SOD1 and diabetic kidney disease: The administration of fucoidan nanoparticles was only at a dose of 300 mg/kg b.w. decreased MDA levels and increased SOD and GPx expression significantly (p < 0.05) as compared with the streptozotocin-induced diabetic nephropathy.